^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)

    i
    Other names: HSD17B2, Hydroxysteroid 17-Beta Dehydrogenase 2, SDR9C2, Short Chain Dehydrogenase/Reductase Family 9C Member 2, Microsomal 17-Beta-Hydroxysteroid Dehydrogenase, 17-Beta-Hydroxysteroid Dehydrogenase Type 2, 20 Alpha-Hydroxysteroid Dehydrogenase, Testosterone 17-Beta-Dehydrogenase, Estradiol 17-Beta-Dehydrogenase 2, 17-Beta-HSD 2, 20-Alpha-HSD, EDH17B2, HSD17, E2DH, Short Chain Dehydrogenase/Reductase Family 9C, Member 2, Hydroxysteroid (17-Beta) Dehydrogenase 2
    2ms
    17β-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark. (PubMed, Breast Cancer Res)
    HSD17B1 may be a prognostic marker for recurrence and HSD17B2 may be predictive of response to tamoxifen therapy in breast cancer.
    Journal
    |
    ER (Estrogen receptor) • HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    |
    ER positive
    |
    tamoxifen
    7ms
    HSD17B2 serves as a novel tumor-suppressive regulator in colorectal cancer progression. (PubMed, Biochem Biophys Res Commun)
    Functional characterization using three human CRC cell lines (Caco-2, HT-29, and HCT-116) demonstrated that ectopic expression of HSD17B2 significantly suppressed cellular proliferation and colony formation. These findings suggest that HSD17B2 acts as a novel negative regulator in CRC and provide mechanistic insights into CRC pathogenesis that may inform future therapeutic strategies.
    Journal
    |
    HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    12ms
    Biological and therapeutic implications of sex hormone-related gene clustering in testicular cancer. (PubMed, Basic Clin Androl)
    Hormonal cluster #1 or #3 is an independent prognostic factor regarding poor progression-free survival. Hormonal cluster assignment also affects the predicted drug response with cluster-dependent susceptibility to specific novel therapeutic compounds.
    Journal
    |
    CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1) • GNRH1 (Gonadotropin Releasing Hormone 1) • HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2) • PRL (Prolactin) • SRD5A1 (Steroid 5 Alpha-Reductase 1) • STAR (Steroidogenic Acute Regulatory Protein)
    1year
    Unveiling the substantial role of rutin in the management of drug-induced nephropathy using network pharmacology and molecular docking. (PubMed, Int Immunopharmacol)
    The revelation of mode of action of bioactive constituent rutin against drug-induced nephropathy provides a theoretical basis for designing more promising compounds in future for treatment of nephropathy.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • MCL1 (Myeloid cell leukemia 1) • KDR (Kinase insert domain receptor) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PRKCH (Protein Kinase C Eta) • IL2 (Interleukin 2) • PLK1 (Polo Like Kinase 1) • CHEK1 (Checkpoint kinase 1) • SYK (Spleen tyrosine kinase) • PTGS2 (Prostaglandin-Endoperoxide Synthase 2) • ALDH2 (Aldehyde Dehydrogenase 2 Family Member) • IR (Insulin receptor) • MMP9 (Matrix metallopeptidase 9) • SERPINE1 (Serpin Family E Member 1) • CDK1 (Cyclin-dependent kinase 1) • CXCR1 (Chemokine (C-X-C motif) receptor 1) • HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2) • MAPT (Microtubule Associated Protein Tau) • NOX4 (NADPH Oxidase 4) • PDE5A (Phosphodiesterase 5A) • PRKACA (Protein Kinase CAMP-Activated Catalytic Subunit Alpha) • PRKCA (Protein Kinase C Alpha) • PRKCB (Protein Kinase C Beta) • CYP1B1 (Cytochrome P450 Family 1 Subfamily B Member 1) • KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2) • MMP3 (Matrix metallopeptidase 3) • PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)
    over1year
    Profiling steroid hormone landscape of bladder cancer reveals depletion of intratumoural androgens to castration levels: a cross-sectional study. (PubMed, EBioMedicine)
    By revealing the steroid landscape of bladder cancer, our study not only underscores the androgen-poor nature of the malignancy but also identifies potential alterations in steroid profiles that are linked to disease aggressiveness.
    Observational data • Journal
    |
    AR (Androgen receptor) • HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    |
    AR expression
    over2years
    17β-Hydroxysteroid dehydrogenases types 1 and 2: Enzymatic assays based on radiometric and mass-spectrometric detection. (PubMed, Methods Enzymol)
    HSD17B1 and HSD17B2 overexpressing E.coli homogenates or recombinant enzymes can be used for screening and development of drugs against various pathologies such as cancer, endometriosis or osteoporosis. Here we describe the preparation of HSD17B1 and HSD17B2 bacterial homogenates and purified recombinant HSD17B1 protein as enzyme sources as well as enzymatic assays based on radiometric and mass-spectrometric detection for enzyme characterization.
    Journal
    |
    ER (Estrogen receptor) • HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    |
    HSD17B2 overexpression
    over2years
    Single-cell RNA sequencing reveals that HSD17B2 in cancer-associated fibroblasts promotes the development and progression of castration-resistant prostate cancer. (PubMed, Cancer Lett)
    HSD17B2 in CAFs regulated AR activation and subsequent ITGBL1 secretion to promote the malignant behaviour of PCa cells. HSD17B2 in CAFs could serve as a promising therapeutic target for CRPC.
    Journal
    |
    HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    3years
    Analysis of high risk factors for chronic atrophic gastritis. (PubMed, Saudi J Gastroenterol)
    Non-invasive tests include the combination of serum pepsinogen II protein and pepsinogen I/II ratio and high level of serum testosterone. UBT combined with serum pepsinogen testing may improve the positive rate of CAG and reduce gastric mucosal damage from multiple biopsies.
    Journal
    |
    HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    over3years
    Transcriptomic Response to Calcium in Normal Colon Organoids is Impacted by Colon Location and Sex. (PubMed, Cancer Prev Res (Phila))
    Calcium supplementation increased differentiation and altered expression of colorectal cancer-related genes in a large study of patient-derived colon organoids. These findings were influenced by colon location and sex.
    Journal
    |
    HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    over4years
    Differential but Concerted Expression of HSD17B2, HSD17B3, SHBG and SRD5A1 Testosterone Tetrad Modulate Therapy Response and Susceptibility to Disease Relapse in Patients with Prostate Cancer. (PubMed, Cancers (Basel))
    We also showed that metronomic dutasteride synergistically enhanced the anticancer effect of low-dose docetaxel, in vitro, and in vivo. These data provide proof of concept that re-reprogramming of testosterone metabolism through "SRD5A1 withdrawal" or "SHBG induction" is a workable therapeutic strategy for shutting down androgen-driven oncogenic signals, reversing treatment resistance, and repressing the metastatic/recurrent phenotypes of patients with PCa.
    Clinical • Journal
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCC1 (ATP Binding Cassette Subfamily C Member 1) • KLF4 (Kruppel-like factor 4) • HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    |
    docetaxel
    almost5years
    [VIRTUAL] 17β-hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark (AACR 2021)
    We observed that HSD17B1 expression was associated with a higher rate of recurrence among premenopausal women, and that HSD17B2 expression was associated with a lower rate of recurrence among premenopausal tamoxifen-treated women diagnosed with ER+ disease. HSD17B1 may be an important prognostic marker of breast cancer recurrence among premenopausal breast cancer patients and HSD17B2 may be predictive of response among tamoxifen-treated premenopausal women diagnosed with ER+ breast cancer.
    Clinical
    |
    ER (Estrogen receptor) • HSD17B2 (Hydroxysteroid 17-Beta Dehydrogenase 2)
    |
    ER positive
    |
    tamoxifen